Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 547-560

  Paolini, John F ^a   Bays, Harold E ^b   Ballantyne, Christie M ^c   Davidson, Michael ^d   Pasternak, Richard ^a   Maccubbin, Darbie ^a   Norquist, Josephine M ^a   Lai, Eseng ^a   Waters, M Gerard ^a   Kuznetsova, Olga ^a   McCrary Sisk, Christine ^a   Mitchel, Yale B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d RADIANT RESEARCH   (United States)

Author keywords

Cardiovascular risk; Extended release niacin; Flushing; Laropiprant; Prostaglandin D2

Indexed keywords

ACETYLSALICYLIC ACID; CLOFIBRATE; COLESTIPOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY RISK; CREATINE KINASE BLOOD LEVEL; DELAYED RELEASE FORMULATION; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG UTILIZATION; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERLIPIDEMIA; INSOMNIA; ISCHEMIC HEART DISEASE; MYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT;

ANIMALS; ANTILIPEMIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DYSLIPIDEMIAS; FLUSHING; HUMANS; INDOLES; LIPIDS; NIACIN; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 53149118986     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.06.007     Document Type: Review

References (53)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J Am Med Assoc 285 19 (2001) 2486-2497
2. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
3. Stamler J., Daviglus M.L., Garside D.B., et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality, and to longevity. J Am Med Assoc 284 3 (2000) 311-318
4. DeBacker G., Amronsione E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10 (2003) S1-S78
5. Gotto A.M. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 144 (2002) S33-S42
6. Shah P.K., Kaul S., Nilsson J., et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins-an idea whose time for testing is coming, part I. Circulation 104 (2001) 2376-2383
7. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 1 (1989) 8-15
8. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 54 (2003) 321-341
9. Durrington P.N. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 141 Suppl 1 (1998) S57-S62
10. Jeppesen J., Hein H.O., Suadicani P., et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97 11 (1998) 1029-1036
11. Austin M.A., Hokanson J.E., and Edwards K.L. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81 4a (1998) 7b-12b
12. Assmann G., Schulte H., Funke H., et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 19 Suppl M (1998) 8-14
13. Brunzell J.D. ADA/ACC consensus statement. Diabetes Care 31 (2008) 811-822
14. Offermanns S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol Sci 27 7 (2006) 384-390
15. Altschul R., Hoffer A., and Stephen J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54 (1955) 558-559
16. Carlson L.A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258 (2005) 94-114
17. Mahley R.W., and Bersot T.P. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). The pharmacological basis of therapeutics. 10th edition (2001), Goodman and Gillman's, New York 971-1002
18. National Institutes of Health. National Cholesterol Education Program (NCEP) Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
19. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2 (2000) 36-46
20. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 231 4 (1975) 360-381
21. Brown B.G., Zhao X.-Q., Chait A., et al. Simvastatinstatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 22 (2001) 1583-1592
22. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
23. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen-year mortality in coronary drug project patients long-term benefit with niacin. J Am Coll Cardiol 8 6 (1986) 1245-1255
24. Blankenhorn D.H., Nessim S.A., Johnson R.L., et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 257 (1987) 3233-3240
25. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 19 (1990) 1289-1298
26. Birjmohun R.S., Hutten B.A., Kastelein J.J., et al. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 62 (2004) 229-234
27. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (NIASPAN): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 29U-34U
28. Guyton J.R., and Bays H.E. Safety considerations with niacin therapy. Am J Cardiol 99 6A (2008) 32C-34C
29. Abbott Pharmaceuticals. NIASPAN (niacin extended-release tablets) US prescribing information. Copyright. Available at: (2005). http://www.rxabbott.com/pdf/niaspantablet.pdf Accessed August 8, 2008
30. Knopp R.H., Alagona P., Davidson M., et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47 9 (1998) 1097-1104
31. Kamal-Bahl, Burke T., and Watson D. Dosage, titration, and gaps in treatment with extended- release niacin in clinical practice. Curr Med Res Opin 24 6 (2008) 1817-1821
32. Kamal-Bahl S., Burke T., Watson D., et al. Discontinuation of lipid-modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 99 (2007) 530-534
33. Kamal-Bahl S., Watson D.J., Kramer B., et al. Flushing experience and discontinuation with niacin in clinical practice. J Am Coll Cardiol 49 9 Suppl A (2007) 273A
34. Trovato A.T., Norquist J.M., Rhodes T., et al. The impact of niacin-induced flushing during the first week of therapy in a real-world setting. J Am Coll Cardiol 51 Suppl 1 (2008) A255
35. Morrow J.D., and Roberts L.J. Lipid-derived autacoids, eicosanoids, and platelet-activating factor. In: Hardman J.G., Limbird L.E., and GIlman A.G. (Eds). The pharmacological basis of therapeutics. 10th edition (2001), Goodman and Gillman's, New York 669-685
36. Jungnickel P.W., Maloley P.A., Vander Tuin E.L., et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 12 (1997) 591-596
37. Morrow J.D., Parsons W.G., and Roberts L.J. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 38 2 (1989) 263-274
38. Wilkin J.K., Wilkin O., Kapp R., et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 31 4 (1982) 478-482
39. Whelan A.M., Price S.O., Fowler S.F., et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 34 2 (1992) 165-168
40. Svedmyr N., Heggelund A., and Aberg G. Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol Toxicol 41 (1977) 397-400
41. Phillips W.S., and Lightman S.L. Is cutaneous flushing prostaglandin-mediated?. Lancet 1 (1981) 754-756
42. Wilkin J.K., Fortner G., Reinhardt L.A., et al. Prostaglandins and nicotinate-provoked increase in cutaneous blood flow. Clin Pharmacol Ther 38 (1985) 273-277
43. Nozaki S., Kihara S., and Kubo M. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol 25 12 (1987) 643-647
44. Eklund B., Kaijser L., Nowak J., et al. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17 6 (1979) 821-830
45. Heavy D.J., Lumley P., Barrow S.E., et al. Effects of intravenous infusions of prostaglandin D2 in man. Prostaglandins 28 (1984) 755-767
46. Cheng K., Wu T.J., Wu K.K., et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 103 17 (2006) 6682-6687
47. Lai E., De Lepeleire I., Crumley T.M., et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 81 (2007) 849-857
48. Norquist J.M., Watson D.J., Yu Q., et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 23 7 (2007) 1549-1560
49. Sheehan K.H., and Sheehan D.V. Assessing treatment effects in clinical trials with the discan metric of the Sheehan disability scale. Int Clin Psychopharmacol 23 2 (2008) 70-83
50. Paolini J.P., Mitchel Y.B., Reyes R., et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol 101 (2008) 625-630
51. Maccubbin D., Bays H.E., Olsson A.G., et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolemia or mixed dyslipidemia. Int J Clin Pract (2008) In press
52. Gleim G., Liu N., Thompson-Bell S., et al. Lipid-altering efficacy and safety profile of coadministered extended-release niacin/laropiprant and simvastatin in patients with dyslipidemia. Circulation 116 (2007) II 127 [abstract 683]
53. Merck & Co., Inc., Study memo; data on file.